Clinical Trials Logo

Spasm clinical trials

View clinical trials related to Spasm.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06432452 Not yet recruiting - Coronary Spasm Clinical Trials

Efficacy of Endothelin Receptor Antagonism in Coronary Artery Spasm

EDIT-CAS
Start date: August 1, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

The goal of this randomized clinical trial is to assess if adjunctive bosentan therapy, in comparison to placebo, can reduce the rate of epicardial vasospasm at follow-up spasm provocation CFT (fuCFT) in patients with previously proven epicardial vasospasm on acetylcholine reactivity testing (at index CFT) and ongoing angina(-like) complaints. Participants will - Use either endothelin receptor antagonist or placebo for 10 weeks - Undergo follow-up acetylcholine spasm provocation test after 10 weeks - Answer online questionnaires on angina and quality of life

NCT ID: NCT06408766 Not yet recruiting - Clinical trials for Smartphone Addiction

Investigating the Effects of Smartphone Use on the Masseter Muscle

Start date: May 30, 2024
Phase:
Study type: Observational

The aim of this study was to determine the short- and long-term effects of smartphone use on the masseter muscle. In the short term, to investigate whether repetitive thumb movements during phone use will cause a spontaneous muscle activation and/or tenderness in the masseter muscle; in the long term, to investigate the relationship between strength change and tenderness of the tenar and masseter muscles depending on the intensity and duration of phone use.

NCT ID: NCT06315829 Not yet recruiting - Infantile Spasms Clinical Trials

Artificial Intelligence-based Video Analysis to Detect Infantile Spasms

Start date: August 2024
Phase:
Study type: Observational

Infantile spasms are a type of seizure linked to developmental issues. Unfortunately, they are often misdiagnosed, causing delays in treatment. The purpose of this study is to develop a computer program that can reliably differentiate infantile spasms from similar, yet benign movements in videos. This computer program will learn from videos taken by parents of study participants. Quickly recognizing and treating infantile spasms is crucial for ensuring the best developmental outcomes.

NCT ID: NCT06195241 Not yet recruiting - Hemifacial Spasm Clinical Trials

Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm

Start date: July 2024
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to test the effects of DaxibotulinumtoxinA-Lanm (Daxxify) in patients with benign essential blepharospasms (BEB) and hemifacial spasms (HFS). The main questions to answer: 1. Is there clinically significant difference (measured by Jankovic Rating Scale (JRS) score from base to peak efficacy) for patients with BEB and HFS treated with Daxxify? 2. What percentage of patients achieve a clinical response? Participants historically treated with Botox for either BEB or HFS will be crossed over to Daxxify treatment in order to serve as their own control and examine the efficacy of Daxxify.

NCT ID: NCT05980637 Not yet recruiting - Clinical trials for Sleep-related Leg Cramps

Effectiveness and Safety of Shaoyao Gancao Decoction With Addition on the Sleep-related Leg Cramps

Start date: September 1, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

A randomized, double-blinded, placebo-controlled clinical trial using a Chinese Medicine formula in treating Sleep-related Leg Cramps. Subjects will be randomized into a treatment group or placebo group for 4 weeks, and then post-treatment visit at week 6 and week 8.

NCT ID: NCT04589364 Not yet recruiting - Hemifacial Spasm Clinical Trials

Study of Abobotulinum Toxin Versus Neubotulinum Toxin Injection For Hemifacial Spasm in Thai Patients

DNHFS
Start date: May 1, 2024
Phase: Phase 3
Study type: Interventional

A 50-Week Prospective, Double-Blinded, Randomized, Cross-over design in Multicenter Study of 100 unit of Abobotulinum Toxin Type A (Dysport®) versus 33.33 unit of Neubotulinum Toxin Type A (Neuronox®) Injection for Hemifacial Spasm in Thai Patients, designed gor comparing the effectiveness of Total intensity score after 4. 12. 16 and 24 weeks of treatment and to compare the long-term safety of the injections. Abobotulinum toxin A (Dysport *) dose 100 units compared ot neubotulinum toxin A injection (Neuronox / Neuronox®) dose 33.33 units. that it si non-inferiority (non-inferiority) ni the treatment of hemifacial spasm after administration of the drug ni the 0, 12" ,26", and 38" weeks ni the treatment of patients with hemi facial spasm, with a wash out period of 2 weeks between treatments. By proving the non-inferiority of Total intensity score at ,4 ,8 and12 week after treatment which calculated by severity score and duration of facial muscle spasm (hour per day)., as well as severity score and duration of functional impairment (hour per day) recorded for 4,8, and 21 weeks after each treatment between 33.33 unit of Neubotulinum Toxin Type A(Neuronox*) and 100 unit of Abobotulinum Toxin Type A (Dysport*)

NCT ID: NCT04474977 Not yet recruiting - Hemifacial Spasm Clinical Trials

Microvascular Decompressive Surgery for Hemifacial Spasm

Start date: September 1, 2020
Phase:
Study type: Observational

- Review the clinical outcomes of Micro vascular decompression of Hemi facial Spasm. - Assess safety and efficacy of Micro vascular decompression. - Improve the outcome of these patients and decease rate of recurrence and complications.

NCT ID: NCT03082625 Not yet recruiting - Clinical trials for Chronic Kidney Diseases

Topical Magnesium and Muscle Cramps in Dialysis Patients.

Start date: May 1, 2017
Phase: Phase 2
Study type: Interventional

Oral magnesium supplementation has been widely used in the treatment of muscle cramps. Muscle cramps are common in dialysis patients but are not satisfactorily prevented by oral magnesium. Transdermal administration of magnesium has been promoted as a potential treatment for muscle cramps but this has not been investigated rigorously. We aim to evaluate the effectiveness of transdermal magnesium supplementation in reducing cramp frequency and severity. We will recruit current haemodialysis patients who suffer from muscle cramps into a randomised, placebo-controlled, cross-over design trial. Each intervention period will last 8 weeks with a 4-week washout period in between. We will measure muscle cramp frequency, duration and severity as the primary outcomes.

NCT ID: NCT02642861 Not yet recruiting - Liver Cirrhosis Clinical Trials

Cyclobenzaprine in Muscle Cramps With Liver Cirrhosis

Start date: October 2018
Phase: Phase 3
Study type: Interventional

- Cyclobenzaprine, is a muscle relaxer medication used to relieve skeletal muscle spasms. It is one of the best-studied drug for this application.

NCT ID: NCT02642484 Not yet recruiting - Liver Cirrhosis Clinical Trials

Gabapentin in Treatment of Muscle Cramps in Patients With Liver Cirrhosis

Start date: December 2018
Phase: Phase 3
Study type: Interventional

- Muscle cramps markedly affect the quality of life in cirrhotic patients with no highly effective drug. - Quinine was suggested for treatment of patients with muscle cramps in patients with liver cirrhosis. However, thrombocytopenia, cardiac arrhythmias and cinchonism are serious side effects.